SCHEMBL2473783

SCHEMBL2473783

CN(C)CCCC(NC(=O)NCc1ccco1)c1ccc(C(=O)Nc2ccccc2NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 5/20 0.42
ALDH1A1 P00352 4/20 0.40
TSHR P16473 4/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HSD17B10 Q99714 1/20 0.40
GAA P10253 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.38
HDAC1 Q13547 1/20 0.38
HPGD P15428 4/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
EPHX2 P34913 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476432 0.86 UTS2R (0.46) UTS2RALDH1A1TSHRNPSR1HSD17B10
SCHEMBL2475946 0.83 UTS2R (0.46) UTS2RHDAC1EPHX2
SCHEMBL2480439 0.81 UTS2R (0.47) UTS2RHDAC1
SCHEMBL2474055 0.81 UTS2R (0.47) UTS2RKDM4ERAB9AHDAC1SMN1; SMN2
SCHEMBL2478100 0.80 UTS2R (0.44) UTS2RHSD17B10GAA
SCHEMBL2479563 0.80 UTS2R (0.44) UTS2RHDAC1
SCHEMBL4397087 0.79 HDAC1 (0.48) ALDH1A1TSHRNPSR1HSD17B10KDM4E
SCHEMBL10476427 0.79 UTS2R (0.39) UTS2RALDH1A1TSHRHSD17B10GAA
SCHEMBL2475610 0.79 NAMPT (0.52) UTS2RRAB9AHDAC1SMN1; SMN2
SCHEMBL2475578 0.79 UTS2R (0.47) UTS2RGAARAB9AHDAC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 UTS2R 11/4885ALDH1A1 1040/4885TSHR 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.